#USA #Rockville #Biopharmaceutical #OncoC4 #Steve Chen

OncoC4's Leadership Expansion: Welcoming Dr. Steve Chen

On September 1, 2026, OncoC4, Inc., a prominent biopharmaceutical company at the forefront of developing innovative treatments for cancer and neurodegenerative diseases, announced a significant addition to its leadership team. Dr. Steve Chen, JD, PhD, has been appointed as General Counsel. This move signals OncoC4's commitment to strengthening its legal framework as it advances its clinical programs and horizontal growth.

Dr. Chen brings nearly two decades of multifaceted experience in legal, corporate, and strategic roles within the biotechnology industry. His previous positions include serving as General Counsel for HiFiBiO Therapeutics and ENSEM Therapeutics, where his responsibilities ranged from corporate governance and intellectual property to regulatory compliance and business development. Furthermore, his tenure at DSM allowed him to hone his leadership skills in legal and intellectual property matters, making him an invaluable asset for OncoC4.

What sets Dr. Chen apart is his unique background; he began his career in the scientific arena as a researcher with Vertex Pharmaceuticals before transitioning to the legal profession. This dual expertise equips him with a distinctive ability to unify scientific innovation with effective legal and business strategies. His legal experience at Jones Day, where he provided counsel to life sciences firms on patent-related issues, only bolsters this qualification.

In his new role, Dr. Chen will assist OncoC4 in navigating the complex landscape of corporate governance as the company continues to scale its global operations and value partnerships. Yang Liu, PhD, Founder and CEO of OncoC4, expressed enthusiasm over Dr. Chen’s addition: “Steve's combination of legal judgment, scientific training, and extensive biotechnology industry experience makes him an excellent addition to our leadership team.” Liu acknowledged that as OncoC4 moves forward with multiple clinical initiatives, Dr. Chen's expertise will be essential for supporting their corporate governance and intellectual property strategy.

Dr. Chen expressed his excitement at joining OncoC4, stating, “OncoC4 has built an innovative pipeline grounded in deep scientific insight and has reached an important stage in its development.” He is particularly eager to contribute to the advancement of AI-081, a novel PD-1/VEGF bispecific antibody, and ONC-841, which is being evaluated for both oncology and neurodegenerative conditions. His vision aligns with the company's goal to safeguard its innovations while helping execute strategic priorities that can ultimately lead to meaningful therapies for patients in need.

Established in Rockville, Maryland, OncoC4 aims to transform the landscape of biopharmaceuticals with cutting-edge biologics designed for treating both cancer and immunological disorders. Its diverse pipeline includes candidates with first-in-class and best-in-class potential, targeting new and validated markers across its focus areas. For example, AI-081 (cesalatamig) is a promising bispecific antibody currently in rapid global clinical development, while ONC-841 is pioneering as a first-in-class anti-SIGLEC-10 antibody, actively undergoing trials for both oncology and neurodegenerative diseases. Additionally, OncoC4 collaborates with BioNTech on a tumor-selective therapy in pivotal trials, showcasing its commitment to novel approaches in healthcare.

In summary, Dr. Steve Chen's appointment as General Counsel of OncoC4 marks a strategic growth phase for the company, reflecting its robust ambition to protect and expand its innovative contributions to the biopharmaceutical sector. As OncoC4 embarks on this exciting journey, stakeholders are poised to see how its legal and strategic foundations will help drive the company toward its overarching goal of improving patient lives across various challenging medical landscapes.